RecruitingAtopic Dermatitis

Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults

Eligible age

12+ yrs

Accepts

All genders

Locations

23 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.

Sponsor: Galderma R&D

You may qualify if…

✓ Participants who, according to the treating physician's decision and in line with the local package label, start treatment with nemolizumab (Nemluvio®).
✓ Adolescent and adult participants aged \>=12 years with moderate-to-severe AD.
✓ Participants who signed the written informed consent form (ICF) or had it signed by their legal representative.

You may not qualify if…

✕ Have contraindication(s) for the use of nemolizumab (Nemluvio®) according to the local package label.
✕ Participants who received treatment with a drug under clinical development/investigation within 3 months prior to baseline.
✕ Participants who received nemolizumab previously.
✕ Participants who are mentally, physically, or linguistically unable to understand the content of the ICF and/or to complete the study questionnaires.